MIRD-237 holds substantial promise for the treatment and diagnosis of certain cancers. Its potential clinical applications include:
Background and Scope MIRD publications are developed to support accurate, reproducible calculations of radiation dose delivered to organs and tissues from radiopharmaceuticals. MIRD-237 specifically addresses approaches for voxel-based dosimetry using quantitative imaging. It builds on earlier MIRD reports that established basic concepts such as S-values (mean absorbed dose to a target per nuclear transformation in a source), reference phantoms, and time–activity integration, adapting those concepts to modern three-dimensional imaging data (CT, SPECT, PET) and voxelized representations of anatomy and activity distributions. MIRD-237
As research into MIRD-237 continues to unfold, we can expect to see new and innovative applications emerge. The medical community is eagerly anticipating the potential benefits that this isotope can bring, from improved patient outcomes to enhanced our understanding of human disease. MIRD-237 holds substantial promise for the treatment and